Displaying 207 (all) recruiting clinical trials.
-
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
Phase
Interventional
-
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or ...
Phase
Interventional
-
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
The goal of this Phase II study is to evaluate the safety/tolerability and clinical activity of the combination of nab-paclitaxel and the antibody against ...Phase
Interventional
-
Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic ...
Phase
Interventional
-
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma Response and Biology-Based Risk factor-guided therapy in treating younger patients with non-high Neuroblastoma
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor ...
Phase
Interventional
-
A randomized phase II trial of fulvestrant with or without Ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive HER2 negative breast cancer
This is a phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate fulvestrant +/- ribociclib in patients with HR+HER2- breast cancer who have previously progressed ...
Phase
Interventional
-
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study which will be conducted in 2 parts: a dose-escalation part and a dose expansion part. Patients with ...
Phase
Interventional
-
AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)
If you are the parent or guardian of a child/adolescent diagnosed with acute lymphoblastic leukemia, your child may qualify to participate in a clinical ...
Phase
Interventional
-
AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
If you are the parent or guardian of a child diagnosed with acute myeloid leukemia (AML) also born with Down Syndrome (DS), your child may ...
Phase
Interventional
-
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
The main goal of this phase III study is to evaluate whether adjuvant therapy with crizotinib (an ATP blocker of several tyrosine kinases) will result ...
Phase
Interventional
